A comprehensive analysis found that most patients received “zero or close to zero” discount on the price of their drugs even though those treatments were purchased at steep discounts through the 340B program.
A comprehensive analysis found that most patients received “zero or close to zero” discount on the price of their drugs even though those treatments were purchased at steep discounts through the 340B program.
Our trusted Connecticut public policy reporting is always free to read. Get it directly in your inbox every morning.
You'll get newsletter-exclusive insights and commentary so you can be part of the conversation.
